This transcript has been edited for clarity.

Hi, I’m Steve Sarkisian, MD, founder and CEO of Oklahoma Eye Surgeons in Oklahoma City. This year, 2026, at the American Glaucoma Society meeting, we are talking about iDose TREX, which is a sustained-release travoprost implant. I’m presenting data from our very early study of 10 patients who received the extended-release travoprost implant made by Glaukos.

My colleagues and I were able to present both 11-day follow-up and 6-week follow-up data. Of note, TREX is a procedural pharmaceutical, not a MIGS, but it lowers pressure by placing the extended-release implant inside the eye. The mean pressure at baseline was 24.3 mmHg.

What was amazing was that even at day 11, pressure dropped by 44%, or 10.8 mmHg. Then at week 6, it was a 37% drop in pressure. So really, really impressive. We didn’t have any adverse events.

We’re excited to see this second-generation travoprost extended-release implant. It has twice as much drug capacity as the commercially available iDose TR that’s on the market now.

Again, it’s something that can be done by itself or combined with phaco, and I’ve done both. I’ve done hundreds of iDose TR procedures since it was FDA approved [in December 2023]. We also have 2 very robust randomized clinical trials that demonstrate the safety and efficacy of iDose TR. So it’s exciting to be able to present the next generation of procedural pharmaceuticals. I’m excited to see what’s going to happen over the rest of the decade as all these amazing things unfold, and I was excited to present this data at AGS. GP